ArticleAnnals of hematology2026

Early deep response to cilta-cel as 2nd CAR T-Cell therapy after CELMoD-based bridging for advanced multiple myeloma.

Henrik Niklas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.